HAWA Therapeutics
Athens
About HAWA Therapeutics
HAWA Therapeutics creates a novel treatment for muscle strain, damage, and dystrophy stimulating muscle stem cell functions. The treatment involves injecting HIF2ai inhibitors into the muscle, but the company is also exploring topical and oral approaches. Moderate and severe muscle strains can cause immense pain, causing people to be out of work for long periods of time. Treatment options are limited to physical therapy, surgery, and a host of short-term drugs such as anti-inflammatories. Severe strains often heal incompletely, making people susceptible to further injury. HAWA’s HIF2Ai technology accelerates initial recovery and reduces recurrent injuries by preventing the formation of scar tissue.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $25.0K
- Funding stage: Seed
- Last round: Seed (Aug 2019)
Industries & Categories
Biopharma, Pharmaceutical, Therapeutics
Canonical: https://fsome.com/organization/hawa-therapeutics-2220337 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.